Healthcare, a fundamental human right, shouldn’t feel like a luxury cruise line — exorbitant price tag and all. Yet, this is the reality for many, thanks in part to the astronomical costs of new drugs. The pharmaceutical industry, a relentless engine of innovation, churns out life-saving (and life-changing) medications, but at a price that often leaves patients gasping for air. And we’re forced to ask: are we paying too much for a healthy future?
GSK will buy asthma drug developers for up to $1.4 billion in a pipeline push. GSK’s acquisition comes as the British firm seeks to boost its pipeline to keep up with rivals amid a flurry of deals in the pharmaceutical sector that has seen top drugmakers seeking to cash in on fast-paced developments in medical sciences by snapping up innovative biotechs. Significant deals include Bristol Myers Squibb’s BMY, -0.84% $14 billion acquisition of Karuna Therapeutics. Those deals have to be paid for.